Caravaca Francisco, Gonzales Boris, Bayo Miguel Ángel, Luna Enrique
Servicio de Nefrología, Hospital Infanta Cristina, Badajoz, España.
Servicio de Nefrología, Hospital Infanta Cristina, Badajoz, España.
Nefrologia. 2016 Jul-Aug;36(4):433-40. doi: 10.1016/j.nefro.2016.03.024. Epub 2016 Jun 3.
Chronic musculoskeletal pain (CMP) is a very common symptom in patients with chronic kidney disease (CKD), and is associated with a significant deterioration in quality of life.
To determine the prevalence and clinical characteristics associated with CMP in patients with advanced CKD not on dialysis, and to analyse their relation with other uraemic symptoms and their prognosis significance.
Cross-sectional study to analyse the uraemic symptoms of an unselected cohort of patients with CKD stage 4-5 pre-dialysis. In order to characterise patients with CMP, demographic and anthropometric data were collected, as well as data on comorbidities and kidney function. In addition, inflammatory parameters, uric parameters, bone mineral metabolism including 25-hydroxycholecalciferol (25-OHCC), creatine kinase and drugs of potential interest including allopurinol, statins and erythropoiesis-stimulating agents were recorded.
The study group consisted of 1169 patients (mean age 65±15 years, 54% male). A total of 38% of patients complained of CMP, and this symptom was more prevalent in women than in men (49 vs. 28%; P<.0001). Muscle weakness, pruritus, muscle cramps, ecchymosis, insomnia, oedema and dyspnoea were the most common symptoms associated with CMP. There were no significant associations between serum levels of creatine kinase, 25-OHCC, treatment with allopurinol, statins or erythropoiesis-stimulating agents and CMP. The female gender, elderly age, obesity, comorbidity (mainly diabetes, heart failure or COPD), and elevated levels of inflammatory markers (C-reactive protein and non-neutrophilic leukocytes) were the best determinants of CMP. While patients with CMP showed a worse survival rate, a multivariate analysis adjusted for demographic data ruled out the independent association of CMP with mortality.
CMP is highly prevalent in patients with advanced CKD and is associated with other common symptoms of chronic uraemia. As with the general population, elderly age, the female gender, obesity and some comorbid conditions are the best determinants of CMP. Increased inflammatory markers commonly observed in patients with CMP may have a relevant role in its pathogenesis.
慢性肌肉骨骼疼痛(CMP)是慢性肾脏病(CKD)患者非常常见的症状,与生活质量显著下降相关。
确定未接受透析的晚期CKD患者中CMP的患病率及相关临床特征,并分析其与其他尿毒症症状的关系及其预后意义。
采用横断面研究分析一组未经选择的CKD 4-5期透析前患者的尿毒症症状。为了对CMP患者进行特征描述,收集了人口统计学和人体测量数据,以及合并症和肾功能数据。此外,记录了炎症参数、尿酸参数、骨矿物质代谢指标(包括25-羟胆钙化醇(25-OHCC))、肌酸激酶以及包括别嘌醇、他汀类药物和促红细胞生成素在内的潜在相关药物。
研究组包括1169例患者(平均年龄65±15岁,54%为男性)。共有38%的患者主诉有CMP,且该症状在女性中比男性更普遍(49%对28%;P<0.0001)。肌肉无力、瘙痒、肌肉痉挛、瘀斑、失眠、水肿和呼吸困难是与CMP相关的最常见症状。肌酸激酶、25-OHCC的血清水平、别嘌醇、他汀类药物或促红细胞生成素治疗与CMP之间无显著关联。女性、老年、肥胖、合并症(主要是糖尿病、心力衰竭或慢性阻塞性肺疾病)以及炎症标志物(C反应蛋白和非嗜中性白细胞)水平升高是CMP的最佳决定因素。虽然CMP患者的生存率较差,但经人口统计学数据调整的多变量分析排除了CMP与死亡率的独立关联。
CMP在晚期CKD患者中高度普遍,且与慢性尿毒症的其他常见症状相关。与普通人群一样,老年、女性、肥胖和一些合并症是CMP的最佳决定因素。CMP患者中常见的炎症标志物升高可能在其发病机制中起相关作用。